GATA3

Summary

GATA3 (GATA binding protein 3, HGNC:4172) is a protein-coding gene on chromosome 10p14, encoding Trans-acting T-cell-specific transcription factor GATA-3 (P23771). Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. It is haploinsufficient (ClinGen: sufficient evidence).

This gene encodes a protein which belongs to the GATA family of transcription factors. The protein contains two GATA-type zinc fingers and is an important regulator of T-cell development and plays an important role in endothelial cell biology. Defects in this gene are the cause of hypoparathyroidism with sensorineural deafness and renal dysplasia.

Source: NCBI Gene 2625 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hypoparathyroidism-deafness-renal disease syndrome (Definitive, ClinGen)
• GWAS associations: 111
• Clinical variants (ClinVar): 532 total — 79 pathogenic, 37 likely-pathogenic
• Phenotypes (HPO): 41
• Cancer driver (intOGen): activating (oncogene-like) across 2 cancer types
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• Transcription factor: yes — 214 downstream targets (CollecTRI)
• MANE Select transcript: NM_001002295

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4172
Approved symbol	GATA3
Name	GATA binding protein 3
Location	10p14
Locus type	gene with protein product
Status	Approved
Aliases	HDR
Ensembl gene	ENSG00000107485
Ensembl biotype	protein_coding
OMIM	131320
Entrez	2625

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000346208, ENST00000379328, ENST00000461472, ENST00000481743, ENST00000643001, ENST00000872595, ENST00000955812, ENST00000955813

RefSeq mRNA: 2 — MANE Select: NM_001002295 NM_001002295, NM_002051

CCDS: CCDS31143, CCDS7083

Canonical transcript exons

ENST00000379328 — 6 exons

Exon	Start	End
ENSE00000837293	8055287	8055896
ENSE00000837294	8058305	8058841
ENSE00000837295	8073739	8075198
ENSE00001000938	8054688	8054891
ENSE00001751140	8063993	8064138
ENSE00003626231	8069473	8069598

Expression profiles

Bgee: expression breadth ubiquitous, 220 present calls, max score 99.63.

FANTOM5 (CAGE): breadth broad, TPM avg 67.9772 / max 1664.5110, expressed in 822 samples.

FANTOM5 promoters (22 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103787	44.7207	599
103788	8.5358	569
103786	4.1669	516
103792	3.0694	238
103781	1.8485	181
103791	1.6141	175
103800	1.3228	165
103780	0.5965	155
103790	0.4536	122
103789	0.2963	128

Top tissues by expression

283 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper leg skin	UBERON:0004262	99.63	gold quality
skin of hip	UBERON:0001554	99.47	gold quality
endometrium epithelium	UBERON:0004811	99.47	gold quality
nipple	UBERON:0002030	99.46	gold quality
upper arm skin	UBERON:0004263	99.22	gold quality
mammary duct	UBERON:0001765	98.98	gold quality
epithelium of mammary gland	UBERON:0003244	98.84	gold quality
renal medulla	UBERON:0000362	98.55	gold quality
seminal vesicle	UBERON:0000998	97.92	gold quality
skin of abdomen	UBERON:0001416	97.45	gold quality
mammalian vulva	UBERON:0000997	97.44	gold quality
zone of skin	UBERON:0000014	97.28	gold quality
corpus epididymis	UBERON:0004359	97.03	gold quality
skin of leg	UBERON:0001511	96.80	gold quality
placenta	UBERON:0001987	96.78	gold quality
hair follicle	UBERON:0002073	95.95	gold quality
mucosa of urinary bladder	UBERON:0001259	95.63	gold quality
cauda epididymis	UBERON:0004360	95.42	gold quality
decidua	UBERON:0002450	95.33	gold quality
mammary gland	UBERON:0001911	94.22	gold quality
thoracic mammary gland	UBERON:0005200	94.15	gold quality
buccal mucosa cell	CL:0002336	93.55	gold quality
cervix squamous epithelium	UBERON:0006922	93.37	gold quality
parotid gland	UBERON:0001831	93.29	gold quality
thymus	UBERON:0002370	93.14	gold quality
urethra	UBERON:0000057	92.45	gold quality
penis	UBERON:0000989	92.06	gold quality
amniotic fluid	UBERON:0000173	89.04	gold quality
adult mammalian kidney	UBERON:0000082	88.95	gold quality
kidney	UBERON:0002113	88.03	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 12.

Experiment	Marker?	Max mean expression
E-GEOD-70580	yes	1617.57
E-HCAD-10	yes	938.77
E-MTAB-6701	yes	936.98
E-MTAB-10018	yes	923.50
E-CURD-84	yes	541.65
E-GEOD-114530	yes	486.34
E-MTAB-8142	yes	120.47
E-CURD-119	yes	30.66
E-ANND-3	yes	19.08
E-CURD-122	yes	9.44
E-MTAB-9388	yes	7.23
E-MTAB-6678	yes	6.42
E-CURD-112	no	926.29
E-CURD-89	no	587.72

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

214 targets.

Target	Regulation
ABCB1
ABCC2	Unknown
ABCC3
ACTR6
ADAM2
ALDH1A2	Unknown
ANXA2P3
APBA1	Unknown
ARNT2	Unknown
ATOX1
ATP2B1	Unknown
ATXN10	Unknown
AURKA	Unknown
AURKAIP1
BCAS3	Unknown
BCL2L1	Activation
BHLHE41	Activation
BIRC5
BLCAP	Unknown
BMP2
BPIFB1	Unknown
CALR
CCL27
CCND1	Unknown
CCR5	Repression
CD28
CD38
CD3E
CD4	Activation
CD40LG	Activation

JASPAR motifs

Motif	Name	Family
MA0037.1	GATA3	C4-GATA-related
MA0037.2	GATA3	C4-GATA-related
MA0037.3	GATA3	C4-GATA-related

JASPAR matrix evidence (PMIDs): PMID:8321207

Upstream regulators (CollecTRI, top): AHR, ARID5B, BCL6, E2F1, EBF1, EZH2, FOS, FOXP3, GATA3, GFI1B, HNF1A, HOXB1, IKZF1, JUNB, KMT2A, MEN1, MYB, NFATC2, NFKB1, NOTCH1, PAX8, RBPJ, RELA, RUNX1, SATB1, SMAD1, SMAD5, SP1, SPI1, STAT1, STAT6, TBX21, TBXT, TCF7L2, TP63, ZC3H8, ZEB1, ZNF503

miRNA regulators (miRDB)

128 targeting GATA3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-495-3P	99.96	72.81	4197

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• Strong GATA-3 binding to an oligonucleotide containing two GATA-3 motifs has been mapped at a DNase hypersensitivity site in cluster IV of the CD8 gene complex. (PMID:11937547)
• Identification of an alternative GATA-3 promoter directing tissue-specific gene expression (PMID:11970965)
• A marked reduction in both GATA-3 mRNA and protein expression in HPV-immortalized cell lines was confirmed in cervical carcinoma cell lines. (PMID:12057898)
• GATA-3 transcriptional imprinting in Th2 lymphocytes: a mathematical model. GATA-3 autoactivation creates a bistable system that can memorize a transient inductive signal. (PMID:12087127)
• VZV virus and mite antigens induce expression of this transcription factor in cord blood mononuclear cells, differenetially affecting Th1 and Th2 cells (PMID:12960249)
• GATA-3 is an important transcription factor in regulating human Th2 cell differentiation in vivo. (PMID:14757746)
• GATA3 mutations may have a role in the hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome (PMID:14985365)
• GATA3 plays important roles in the maintenance of the Th2 phenotype and continuous chromatin remodeling of the specific Th2 cytokine gene locus through cell division. (PMID:15087456)
• GATA-3 suppresses IFN-gamma promoter activity independently of binding to cis-regulatory elements (PMID:15251440)
• Erythropoietin (Epo) gene expression is under the control of hypoxia-inducible factor 1 (HIF-1), and is negatively regulated by GATA3. (PMID:15328158)
• GATA3 is involved in growth control and the maintenance of the differentiated state in epithelial cells and may contribute to tumorigenesis in breast cancer. (PMID:15361840)
• GATA-3 contributed to the production of IL-4, IL-5 in patients with allergic rhinitis. (PMID:15563083)
• Expressed in Hodgkin disesase Reed Sternberg cells. (PMID:15632006)
• GATA-3 binds and transactivates the NKG2A promoter; coexpression of human GATA-3 with an NKG2A promoter construct in K562 cells leads to enhanced promoter activity. (PMID:15699146)
• interleukin-5 transcription repression by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment (PMID:15826950)
• GATA3 is crucially involved in IL-5 gene transcription in human peripheral CD4-positive t cells. (PMID:15947486)
• strong specific upregulation of Gata-3 impaired nuclear translocation and its cooperative action with the TGF-beta pathway, suggesting that Gata-3 plays a central role in human pancreatic cancer (PMID:16087702)
• DL1-induced activation of the Notch1 pathway controls the lineage commitment of early thymic precursors by altering the levels between Spi-B and GATA-3. (PMID:16317090)
• Low expression of GATA3 is associated with invasive breast carcinomas (PMID:16357129)
• Segmental allergen challenge in asthmatics leads to increased GATA-3, c-maf and T-bet expression in BAL cells but not in bronchial biopsies (PMID:16498264)
• Direct sequencing after PCR amplification of genomic DNA revealed a novel insertional mutation (405insC) in the GATA3 gene of two patients with HDR syndrome (Hypoparathyroidism, sensorineural Deafness and Renal anomaly syndrome). (PMID:16509533)
• Three novel mutations in the GATA3 gene responsible for familial hypoparathyroidism and deafness. (PMID:16912130)
• Imbalance of transcription factors T-bet and GATA-3 may be one of the key factors in immune dysregulation of recurrent aphthous ulcerations. (PMID:17074191)
• the GATA-3/T-bet transcription factor complex regulates the cell-lineage-specific expression of the lymphocyte homing receptors (PMID:17075044)
• GATA3 is probably a mediator for the transcriptional upregulation of MUC1 expression in some breast cancers. (PMID:17078870)
• Overexpression of GATA3 rescues T-helper type 2 (Th2) cytokine expression in protein kinase C theta-deficient transgenic Th2 cells. (PMID:17111354)
• A novel heterozygous deletion frameshift mutation of GATA3 in a Japanese kindred with the hypoparathyroidism, deafness and renal dysplasia syndrome. (PMID:17114920)
• There is an association between expression of Th1/Th2 transcription factors and cytokines (T-bet, GATA-3, IFN-gamma, IL-4,IL-18) in systemic lupus erythematosus. (PMID:17117487)
• No mutations were identified in patients with isolated hypoparathyroidism, thereby indicating that GATA3 abnormalities are more likely to result in two or more of the phenotypic features of the HDR syndrome. (PMID:17210674)
• The human GATA-3 gene is not regulated in response to polarizing signals that are sufficient to direct Th2-specific expression in mouse cells. (PMID:17234745)
• E2A proteins prevent lymphoma cell expansion, at least in part through regulation of Gfi1b and modulation of Gata3 expression. (PMID:17272506)
• GATA-3 nuclear translocation is dependent on its phosphorylation on serine residues by p38 MAPK (PMID:17277157)
• GATA3 establishes a positive feedback loop that increases transgenic T-cell receptor surface expression in developing CD4 lineage cells. (PMID:17357106)
• Gata-3 has a role in specifying and maintaining mammary cell fate (PMID:17381824)
• WNT8B expression in hepatocyte progenitors derived from human ES cells is due to POU5F1 (OCT3/OCT4) and GATA3, and WNT8B expression in diffuse-type gastric cancer is due to POU5F1 and GATA6 (PMID:17390031)
• In Dermatophagoides farinae-stimulated PBMCs from patients with asthma, expression of GATA-3 and T-bet and FOPX3 expression is decreased. (PMID:17445472)
• In patients with acute asthma, rosiglitazone could regulate the balance of IFN-gamma and IL-4 by affecting expression of T-bet mRNA and GATA-3. (PMID:17445473)
• GATA-3 is a critical component of the master cell-type-specific transcriptional network including ER alpha and FoxA1 that dictates the phenotype of hormone-dependent breast cancer (PMID:17616709)
• Activation of GATA-3 might be one of the mechanisms for induction of IL-5 expression in chronic rhinosinusitis. (PMID:17628972)
• GATA-3 expression in bone marrow stromal cells from chronic aplastic anemia was significantly higher than controls. Expression levels of GATA genes may influence hematopoiesis in BM microenvironment & relate to the pathogenesis/development of AA. (PMID:17654061)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	gata3	ENSDARG00000016526
mus_musculus	Gata3	ENSMUSG00000015619
rattus_norvegicus	Gata3	ENSRNOG00000019336
drosophila_melanogaster	srp	FBGN0003507
drosophila_melanogaster	GATAd	FBGN0032223
caenorhabditis_elegans		WBGENE00001250
caenorhabditis_elegans		WBGENE00001252

Paralogs (7): GATA1 (ENSG00000102145), TRPS1 (ENSG00000104447), GATA5 (ENSG00000130700), GATA4 (ENSG00000136574), GATA6 (ENSG00000141448), GATA2 (ENSG00000179348), ZGLP1 (ENSG00000220201)

Protein

Protein identifiers

Trans-acting T-cell-specific transcription factor GATA-3 — P23771 (reviewed: P23771)

Alternative names: GATA-binding factor 3

All UniProt accessions (4): P23771, A0A2R8Y2A9, A0A2R8Y4T2, A0A994J6H6

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5’-AGATAG-3’. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses. Positively regulates ASB2 expression. Coordinates macrophage transcriptional activation and UCP2-dependent metabolic reprogramming in response to IL33. Upon tissue injury, acts downstream of IL33 signaling to drive differentiation of inflammation-resolving alternatively activated macrophages.

Subunit / interactions. Interacts with TBX21 (‘Tyr-530’ phosphorylated form).

Subcellular location. Nucleus.

Tissue specificity. T-cells and endothelial cells.

Disease relevance. Hypoparathyroidism, sensorineural deafness, and renal disease (HDR) [MIM:146255] A disease characterized by steroid-resistant nephrosis with progressive renal failure, hypoparathyroidism, sensorineural deafness, and renal dysplasia. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. Binds DNA via the 2 GATA-type zinc fingers. Each zinc finger may bind either adjacent sites in a palindromic motif, or a different DNA molecule allowing looping and long-range gene regulation. The YxKxHxxxRP motif is critical for DNA-binding and function.

Isoforms (2)

UniProt ID	Names	Canonical?
P23771-1	1	yes
P23771-2	2

RefSeq proteins (2): NP_001002295, NP_002042 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000679	Znf_GATA	Domain
IPR013088	Znf_NHR/GATA	Homologous_superfamily
IPR016374	TF_GATA-2/3	Family
IPR039355	Transcription_factor_GATA	Family

Pfam: PF00320

UniProt features (35 total): sequence conflict 8, region of interest 7, sequence variant 4, compositionally biased region 3, helix 3, zinc finger region 2, modified residue 2, turn 2, chain 1, short sequence motif 1, splice variant 1, strand 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
4HC9	X-RAY DIFFRACTION	1.6
4HC7	X-RAY DIFFRACTION	2.65
4HCA	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P23771-F1	58.51	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 115, 162

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-5689880	Ub-specific processing proteases
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-8939236	RUNX1 regulates transcription of genes involved in differentiation of HSCs
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9830364	Formation of the nephric duct
R-HSA-983231	Factors involved in megakaryocyte development and platelet production
R-HSA-9938206	Developmental Lineage of Mammary Stem Cells
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)

MSigDB gene sets: 888 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_CARDIAC_CHAMBER_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_REGULATION_OF_CELL_ACTIVATION, VERHAAK_AML_WITH_NPM1_MUTATED_DN, GOBP_PHENOL_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, E2F_Q4_01, GOBP_RESPONSE_TO_ETHANOL, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_EMBRYONIC_HEMOPOIESIS, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_EPITHELIUM_DEVELOPMENT

GO Biological Process (122): negative regulation of transcription by RNA polymerase II (GO:0000122), in utero embryonic development (GO:0001701), cell fate determination (GO:0001709), neuron migration (GO:0001764), type IV hypersensitivity (GO:0001806), regulation of cytokine production (GO:0001817), kidney development (GO:0001822), mesonephros development (GO:0001823), lens development in camera-type eye (GO:0002088), immune system development (GO:0002520), pro-T cell differentiation (GO:0002572), aortic valve morphogenesis (GO:0003180), cardiac right ventricle morphogenesis (GO:0003215), ventricular septum development (GO:0003281), chromatin remodeling (GO:0006338), transcription by RNA polymerase II (GO:0006366), defense response (GO:0006952), inflammatory response (GO:0006954), humoral immune response (GO:0006959), signal transduction (GO:0007165), axon guidance (GO:0007411), cell population proliferation (GO:0008283), negative regulation of cell population proliferation (GO:0008285), male gonad development (GO:0008584), response to xenobiotic stimulus (GO:0009410), response to virus (GO:0009615), anatomical structure morphogenesis (GO:0009653), post-embryonic development (GO:0009791), positive regulation of signal transduction (GO:0009967), response to gamma radiation (GO:0010332), positive regulation of endothelial cell migration (GO:0010595), negative regulation of epithelial to mesenchymal transition (GO:0010719), regulation of neuron projection development (GO:0010975), T cell differentiation (GO:0030217), erythrocyte differentiation (GO:0030218), macrophage differentiation (GO:0030225), regulation of epithelial cell differentiation (GO:0030856), TOR signaling (GO:0031929), negative regulation of type II interferon production (GO:0032689), negative regulation of interleukin-2 production (GO:0032703)

GO Molecular Function (21): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), cis-regulatory region sequence-specific DNA binding (GO:0000987), transcription coactivator binding (GO:0001223), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), interleukin-2 receptor binding (GO:0005134), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), E-box binding (GO:0070888), HMG box domain binding (GO:0071837), histone methyltransferase binding (GO:1990226), sequence-specific double-stranded DNA binding (GO:1990837), RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-8 pathways:

Category	Pathways
Deubiquitination	1
Signaling by Interleukins	1
Transcriptional regulation by RUNX1	1
ESR-mediated signaling	1
Kidney development	1
Hemostasis	1
Developmental Lineages of the Mammary Gland	1
Differentiation of T cells	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
transcription cis-regulatory region binding	3
regulation of transcription by RNA polymerase II	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
cellular anatomical structure	2
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
chordate embryonic development	1
cell fate commitment	1
cellular developmental process	1
cell migration	1
generation of neurons	1
T cell mediated immunity	1
hypersensitivity	1
cytokine production	1
regulation of gene expression	1
regulation of multicellular organismal process	1
animal organ development	1
renal system development	1
kidney development	1
camera-type eye development	1
anatomical structure development	1
immune system process	1
system development	1
lymphoid progenitor cell differentiation	1
T cell differentiation	1
aortic valve development	1
heart valve morphogenesis	1
cardiac ventricle morphogenesis	1
cardiac ventricle development	1
cardiac septum development	1
chromatin organization	1
DNA-templated transcription	1
response to stress	1
defense response	1
immune response	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1

Protein interactions and networks

STRING

5626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GATA3	RUNX1	Q01196	977
GATA3	TBX21	Q9UL17	957
GATA3	FOXA1	P55317	950
GATA3	TAL1	P17542	938
GATA3	ESR1	P03372	911
GATA3	IL4	P05112	909
GATA3	ETS1	P14921	902
GATA3	CD4	P01730	897
GATA3	STAT6	P42226	887
GATA3	IL13	P35225	882
GATA3	IFNG	P01579	880
GATA3	IL5	P05113	876
GATA3	BMI1	P35226	851
GATA3	R4GMX3	R4GMX3	851
GATA3	FOXP3	Q9BZS1	850

IntAct

138 interactions, top by confidence:

A	B	Type	Score
RARA	NCOR1	psi-mi:“MI:0914”(association)	0.800
ESR1	PGR	psi-mi:“MI:0915”(physical association)	0.770
MTA3	MBD3	psi-mi:“MI:0914”(association)	0.690
ESR1	GATA3	psi-mi:“MI:0914”(association)	0.620
MTA3	GATA3	psi-mi:“MI:0914”(association)	0.610
EHMT2	GATA3	psi-mi:“MI:0914”(association)	0.610
GATA3	EHMT2	psi-mi:“MI:0914”(association)	0.610
GATA3	EHMT2	psi-mi:“MI:0407”(direct interaction)	0.610
GATA3	MTA3	psi-mi:“MI:0407”(direct interaction)	0.610
GATA3	GCM1	psi-mi:“MI:0915”(physical association)	0.610
GCM1	GATA3	psi-mi:“MI:0915”(physical association)	0.610
GCM1	GATA3	psi-mi:“MI:0403”(colocalization)	0.610
TBX21	GATA3	psi-mi:“MI:0914”(association)	0.580
TBX21	GATA3	psi-mi:“MI:0915”(physical association)	0.580
TBX21	SP1	psi-mi:“MI:0914”(association)	0.580

BioGRID (226): PSMA3 (Two-hybrid), GATA3 (Biochemical Activity), FBXW7 (Reconstituted Complex), FBXW7 (Affinity Capture-Western), GATA3 (Biochemical Activity), GATA3 (Two-hybrid), WEE1 (Negative Genetic), GATA3 (Affinity Capture-MS), GATA3 (Co-localization), GATA3 (Affinity Capture-Western), TCF7L2 (Affinity Capture-Western), GATA3 (Affinity Capture-Western), GATA3 (Reconstituted Complex), GATA3 (Affinity Capture-MS), GATA3 (Two-hybrid)

ESM2 similar proteins: A0JC51, A5ABV9, O08656, O09100, O18896, O57311, O60481, O73689, O95409, P09022, P10070, P19544, P22561, P23769, P23770, P23771, P23772, P23824, P25932, P46684, P49639, P49952, P54655, P55878, P70062, P70063, Q08DV0, Q0VGT2, Q15915, Q62520, Q62521, Q6DJQ6, Q6VVD7, Q6XP49, Q7TQ40, Q800Q5, Q8JJC0, Q91689, Q924A0, Q924Y4

Diamond homologs: B4XXY3, B7WN96, G5EB20, G5EGF4, G5EGN3, N4XMB0, O09100, O13412, O13415, O13508, O61924, O94720, P15976, P17429, P17678, P17679, P19212, P23767, P23768, P23769, P23770, P23771, P23772, P23773, P23824, P23825, P26343, P28515, P40349, P42944, P43429, P43574, P43691, P43692, P43693, P43694, P43695, P43696, P46152, P46153

SIGNOR signaling

25 interactions.

A	Effect	B	Mechanism
ASH2L	up-regulates	GATA3	binding
GATA3	down-regulates	PPARG	“transcriptional regulation”
GATA3	down-regulates	CEBPA	binding
GATA3	“up-regulates quantity by expression”	ERG	“transcriptional regulation”
GATA3	“up-regulates quantity by expression”	CD8A	“transcriptional regulation”
GATA3	“down-regulates quantity by repression”	FOXC2	“transcriptional regulation”
TBX21	down-regulates	GATA3
GATA3	down-regulates	TBX21
GATA3	up-regulates	GATA3
STAT6	up-regulates	GATA3
GATA3	“up-regulates quantity by expression”	IL4	“transcriptional regulation”
ARID5B	“up-regulates quantity by expression”	GATA3	“transcriptional regulation”
ZNF503	“down-regulates quantity by repression”	GATA3	“transcriptional regulation”
GATA3	“up-regulates quantity by expression”	GLS2	“transcriptional regulation”
PKA	“up-regulates activity”	GATA3	phosphorylation
CDK2	“down-regulates quantity by destabilization”	GATA3	phosphorylation
FBXW7	“down-regulates quantity by destabilization”	GATA3	ubiquitination
GATA3	down-regulates	CEBPB	binding
GATA3	“down-regulates quantity by repression”	PPARG	“transcriptional regulation”
GATA3	“up-regulates activity”	T-lymphocyte_diff
SMAD1	“up-regulates quantity”	GATA3	“transcriptional regulation”
SMAD5	“up-regulates quantity”	GATA3	“transcriptional regulation”
GATA3	down-regulates	Adipogenesis
SMO	“up-regulates activity”	GATA3

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 58 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	10	28.7×	6e-10
NOTCH1 Intracellular Domain Regulates Transcription	6	28.0×	1e-05
Nuclear Receptor transcription pathway	6	23.6×	2e-05
RNA Polymerase I Transcription Initiation	5	21.9×	2e-04
Regulation of PTEN gene transcription	6	21.0×	4e-05
Constitutive Signaling by NOTCH1 PEST Domain Mutants	5	19.3×	3e-04
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	5	19.3×	3e-04
Adipogenesis	5	15.3×	5e-04

GO biological processes:

GO term	Partners	Fold	FDR
neuron fate specification	5	61.6×	2e-06
negative regulation of miRNA transcription	5	54.8×	3e-06
positive regulation of miRNA transcription	7	35.7×	2e-07
epigenetic regulation of gene expression	5	33.6×	3e-05
cerebral cortex development	5	18.0×	4e-04
transcription by RNA polymerase II	9	11.1×	1e-05
chromatin remodeling	8	10.2×	7e-05
neuron differentiation	5	8.8×	6e-03

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 2 cancer types — ALL, BRCA.

Clinical variants and AI predictions

ClinVar

532 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	79
Likely pathogenic	37
Uncertain significance	199
Likely benign	113
Benign	47

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1065344	NM_001002295.2(GATA3):c.389del (p.Leu130fs)	Pathogenic
1174139	NM_001002295.2(GATA3):c.864C>G (p.Cys288Trp)	Pathogenic
1174140	NM_001002295.2(GATA3):c.951del (p.Cys318fs)	Pathogenic
1174524	NM_001002295.2(GATA3):c.778+1G>A	Pathogenic
1185058	NM_001002295.2(GATA3):c.675C>A (p.Tyr225Ter)	Pathogenic
1185679	NM_001002295.2(GATA3):c.352_353del (p.Ser118fs)	Pathogenic
1322981	NM_001002295.2(GATA3):c.779-1G>C	Pathogenic
1365325	NM_001002295.2(GATA3):c.774dup (p.Thr259fs)	Pathogenic
1366705	NM_001002295.2(GATA3):c.836del (p.Gly279fs)	Pathogenic
1406588	NC_000010.10:g.(?8097619)(8739580_?)del	Pathogenic
1452435	NM_001002295.2(GATA3):c.404del (p.Pro135fs)	Pathogenic
1455943	NM_001002295.2(GATA3):c.1050+2T>C	Pathogenic
1456792	NM_001002295.2(GATA3):c.451_454del (p.Phe151fs)	Pathogenic
1527578	GRCh37/hg19 10p14(chr10:7943586-8120292)	Pathogenic
1527579	GRCh37/hg19 10p14(chr10:8046788-9979612)	Pathogenic
16619	GATA3, 900-KB DEL	Pathogenic
16620	GATA3, 250-KB DEL	Pathogenic
16621	NM_001002295.2(GATA3):c.465_513del (p.Thr156fs)	Pathogenic
16622	NM_001002295.2(GATA3):c.947_958del (p.Thr316_Ala319del)	Pathogenic
16624	NM_001002295.2(GATA3):c.823T>A (p.Trp275Arg)	Pathogenic
16625	NM_001002295.2(GATA3):c.901delinsAACCCT (p.Leu301fs)	Pathogenic
16627	NM_001002295.2(GATA3):c.431del (p.Gly144fs)	Pathogenic
16628	NM_001002295.2(GATA3):c.478del (p.Asp160fs)	Pathogenic
16629	NM_001002295.2(GATA3):c.924+2delinsGCTTACTTCCC	Pathogenic
16630	NM_001002295.2(GATA3):c.1059A>T (p.Arg353Ser)	Pathogenic
1678812	NM_001002295.2(GATA3):c.916C>T (p.Arg306Ter)	Pathogenic
1685840	NM_001002295.2(GATA3):c.381_388del (p.Gly128fs)	Pathogenic
1685841	NM_001002295.2(GATA3):c.925-3_925-2del	Pathogenic
1687685	NM_001002295.2(GATA3):c.815C>T (p.Thr272Ile)	Pathogenic
2011955	NM_001002295.2(GATA3):c.638C>A (p.Ser213Ter)	Pathogenic

SpliceAI

910 predictions. Top by Δscore:

Variant	Effect	Δscore
10:8055895:CGGTG:C	donor_loss	1.0000
10:8055897:G:C	donor_loss	1.0000
10:8055898:T:TC	donor_loss	1.0000
10:8055899:GAGT:G	donor_loss	1.0000
10:8063992:GAA:G	acceptor_gain	1.0000
10:8064134:GGCTG:G	donor_gain	1.0000
10:8064135:GCTG:G	donor_gain	1.0000
10:8064135:GCTGG:G	donor_gain	1.0000
10:8064137:TGGTA:T	donor_loss	1.0000
10:8064138:GGTAA:G	donor_loss	1.0000
10:8064139:GTAA:G	donor_loss	1.0000
10:8064140:TAA:T	donor_loss	1.0000
10:8069471:A:AG	acceptor_gain	1.0000
10:8069472:G:GG	acceptor_gain	1.0000
10:8054888:CCAG:C	donor_loss	0.9900
10:8054889:CAG:C	donor_loss	0.9900
10:8054890:AG:A	donor_loss	0.9900
10:8054892:G:GG	donor_loss	0.9900
10:8055135:G:T	donor_gain	0.9900
10:8055281:TTGCA:T	acceptor_loss	0.9900
10:8055282:TGCAG:T	acceptor_loss	0.9900
10:8055283:GCAG:G	acceptor_loss	0.9900
10:8055284:CAGGT:C	acceptor_loss	0.9900
10:8055285:A:AG	acceptor_gain	0.9900
10:8055286:G:GG	acceptor_gain	0.9900
10:8055407:ACCC:A	donor_gain	0.9900
10:8055870:TGCAG:T	donor_gain	0.9900
10:8055897:G:GG	donor_gain	0.9900
10:8058292:C:CA	acceptor_gain	0.9900
10:8058302:CAGGG:C	acceptor_gain	0.9900

AlphaMissense

2899 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:8063999:G:T	R261M	1.000
10:8064001:G:A	E262K	1.000
10:8064004:T:A	C263S	1.000
10:8064004:T:C	C263R	1.000
10:8064005:G:A	C263Y	1.000
10:8064005:G:C	C263S	1.000
10:8064005:G:T	C263F	1.000
10:8064006:T:G	C263W	1.000
10:8064010:A:G	N265D	1.000
10:8064011:A:T	N265I	1.000
10:8064012:C:A	N265K	1.000
10:8064012:C:G	N265K	1.000
10:8064013:T:A	C266S	1.000
10:8064013:T:C	C266R	1.000
10:8064013:T:G	C266G	1.000
10:8064014:G:A	C266Y	1.000
10:8064014:G:C	C266S	1.000
10:8064014:G:T	C266F	1.000
10:8064015:T:G	C266W	1.000
10:8064016:G:A	G267R	1.000
10:8064016:G:C	G267R	1.000
10:8064016:G:T	G267W	1.000
10:8064017:G:A	G267E	1.000
10:8064017:G:T	G267V	1.000
10:8064019:G:C	A268P	1.000
10:8064025:T:C	S270P	1.000
10:8064029:C:A	T271N	1.000
10:8064029:C:T	T271I	1.000
10:8064031:C:T	P272S	1.000
10:8064032:C:A	P272Q	1.000

dbSNP variants (sampled 300 via entrez): RS1000122908 (10:8048425 G>A), RS1000135052 (10:8063370 C>T), RS1000306816 (10:8043584 C>G), RS1000387438 (10:8059251 G>C), RS1000398557 (10:8052900 G>A,C,T), RS1000490579 (10:8049867 C>A), RS1000514237 (10:8046119 A>T), RS1000654323 (10:8069977 G>A,C), RS1000669497 (10:8050364 G>A,T), RS1000725339 (10:8055128 C>G), RS1000786763 (10:8054168 T>C), RS1000931566 (10:8068708 G>A,T), RS1000943956 (10:8053913 C>A,G), RS1000964908 (10:8060540 T>TC), RS1001054865 (10:8044995 T>A,C)

Disease associations

OMIM: gene MIM:131320 | disease phenotypes: MIM:146255, MIM:114480, MIM:610805

GenCC curated gene-disease

Disease	Classification	Inheritance
hypoparathyroidism-deafness-renal disease syndrome	Definitive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hypoparathyroidism-deafness-renal disease syndrome	Definitive	AD

Mondo (8): hypoparathyroidism-deafness-renal disease syndrome (MONDO:0007797), neurodevelopmental disorder (MONDO:0700092), hearing loss disorder (MONDO:0005365), B-cell childhood acute lymphoblastic leukemia (MONDO:0000872), ovarian neoplasm (MONDO:0021068), hereditary breast carcinoma (MONDO:0016419), end stage renal failure (MONDO:0004375), congenital anomaly of kidney and urinary tract (MONDO:0019719)

Orphanet (3): Hypoparathyroidism-sensorineural deafness-renal disease syndrome (Orphanet:2237), Hereditary breast cancer (Orphanet:227535), Renal or urinary tract malformation (Orphanet:93545)

HPO phenotypes

41 total (30 of 41 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000076	Vesicoureteral reflux
HP:0000083	Renal insufficiency
HP:0000093	Proteinuria
HP:0000100	Nephrotic syndrome
HP:0000110	Renal dysplasia
HP:0000113	Polycystic kidney dysplasia
HP:0000121	Nephrocalcinosis
HP:0000122	Unilateral renal agenesis
HP:0000126	Hydronephrosis
HP:0000148	Vaginal atresia
HP:0000151	Aplasia of the uterus
HP:0000175	Cleft palate
HP:0000407	Sensorineural hearing impairment
HP:0000408	Progressive sensorineural hearing impairment
HP:0000508	Ptosis
HP:0000510	Rod-cone dystrophy
HP:0000538	Pseudopapilledema
HP:0000666	Horizontal nystagmus
HP:0000786	Primary amenorrhea
HP:0000790	Hematuria
HP:0000819	Diabetes mellitus
HP:0000829	Hypoparathyroidism
HP:0000860	Parathyroid hypoplasia
HP:0001153	Septate vagina
HP:0001281	Tetany
HP:0001627	Abnormal heart morphology
HP:0002049	Proximal renal tubular acidosis
HP:0002135	Basal ganglia calcification
HP:0002199	Hypocalcemic seizures

GWAS associations

111 associations (top):

Study	Trait	p-value
GCST000851_1	Hodgkin’s lymphoma	7.000000e-08
GCST002083_8	Self-reported allergy	2.000000e-08
GCST002158_2	Acute lymphoblastic leukemia (B-cell precursor)	9.000000e-12
GCST002201_4	Calcium levels	5.000000e-09
GCST002318_110	Rheumatoid arthritis	3.000000e-09
GCST002318_111	Rheumatoid arthritis	2.000000e-08
GCST002411_1	Colorectal cancer	7.000000e-11
GCST002415_8	Colorectal cancer (diet interaction)	9.000000e-09
GCST002480_6	Hodgkin’s lymphoma	3.000000e-06
GCST002713_1	Acute lymphoblastic leukemia (adolescents and young adults)	3.000000e-10
GCST002842_13	Basal cell carcinoma	2.000000e-16
GCST002880_3	Recalcitrant atopic dermatitis	1.000000e-07
GCST002919_9	Colorectal cancer	4.000000e-13
GCST002987_8	Stroke	1.000000e-07
GCST003124_22	Mild influenza (H1N1) infection	3.000000e-08
GCST003155_2	Systemic lupus erythematosus	9.000000e-08
GCST003474_2	Scalp hair shape	4.000000e-08
GCST003726_8	Basal cell carcinoma	3.000000e-23
GCST003814_1	Selective IgA deficiency	5.000000e-08
GCST003987_13	Asthma	8.000000e-12
GCST003990_12	Allergy	6.000000e-11
GCST004227_6	Obstetric antiphospholipid syndrome	8.000000e-07
GCST004412_5	Craniofacial microsomia	5.000000e-09
GCST004606_192	Eosinophil count	7.000000e-09
GCST004638_1	Benign prostatic hyperplasia and/or lower urinary tract symptoms	9.000000e-07
GCST004839_1	Colorectal cancer	9.000000e-08
GCST005038_128	Allergic disease (asthma, hay fever or eczema)	8.000000e-09
GCST005038_129	Allergic disease (asthma, hay fever or eczema)	3.000000e-11
GCST005038_130	Allergic disease (asthma, hay fever or eczema)	2.000000e-22
GCST005038_24	Allergic disease (asthma, hay fever or eczema)	2.000000e-12

EFO canonical traits (14, from GWAS)

EFO ID	Trait name
EFO:0004838	calcium measurement
EFO:0008111	diet measurement
EFO:1000651	recalcitrant atopic dermatitis
EFO:1001488	influenza A (H1N1)
EFO:0004842	eosinophil count
EFO:0008008	lower urinary tract symptom
EFO:0008579	risk-taking behaviour
EFO:0004318	smoking behavior
EFO:1002011	adult onset asthma
EFO:0004469	HOMA-B
EFO:0007991	eosinophil percentage of leukocytes
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
D065886	Neurodevelopmental Disorders	F03.625
C537907	Barakat syndrome (supp.)
C562840	Breast Cancer, Familial (supp.)
C566906	Cakut (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs3824662	Efficacy	3	asparaginase;cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;leucovorin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine
rs3824662	Toxicity	3	glucarpidase	Nephrotoxicity

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3824662	GATA3	3	6.00	2	asparaginase;cyclophosphamide;cytarabine;daunorubicin;dexamethasone;doxorubicin;leucovorin;mercaptopurine;methotrexate;pegaspargase;prednisone;thioguanine;vincristine;glucarpidase

CTD chemical–gene interactions

77 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, increases methylation	7
sodium arsenite	increases abundance, increases stability, decreases reaction, increases expression, affects methylation (+1 more)	6
trichostatin A	decreases expression, increases expression, affects cotreatment	4
bisphenol A	decreases expression	3
Vorinostat	affects cotreatment, increases expression	3
Tretinoin	increases expression	3
methylmercuric chloride	decreases expression, increases expression	2
N’-nitrosonornicotine	increases expression, decreases reaction, increases activity	2
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone	increases activity, increases expression, decreases reaction	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Nickel	decreases expression, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Dronabinol	decreases reaction, increases expression, affects reaction	2
Aflatoxin B1	decreases methylation, increases methylation	2
Cadmium Chloride	decreases expression, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	affects splicing	1
Esketamine	decreases expression	1
Asian ginseng	affects cotreatment, decreases expression	1
triphenyl phosphate	affects expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
arsenite	increases methylation	1
4-hydroxy-2-nonenal	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline	decreases expression, affects cotreatment, increases expression	1
corosolic acid	increases expression	1
rofecoxib	decreases expression	1

Cellosaurus cell lines

751 cell lines: 748 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0031	MCF-7	Cancer cell line	Female
CVCL_0088	MCF-7L	Cancer cell line	Female
CVCL_0404	M7TS90	Cancer cell line	Female
CVCL_0412	MCF-7/2a	Cancer cell line	Female
CVCL_0413	MCF7/BUS	Cancer cell line	Female
CVCL_0415	MCF7mp53	Cancer cell line	Female
CVCL_0U80	MCF-7/HER2-18	Cancer cell line	Female
CVCL_1D32	MCF7 AREc32	Cancer cell line	Female
CVCL_1D38	MCF-7/164R-5	Cancer cell line	Female
CVCL_1D39	MCF-7/164R-7	Cancer cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC